Neoadjuvant Immunotherapy in Gastroesophageal Cancer: A Promising Early Signal?
作者信息
Zhu Mojun, Yoon Harry H
机构信息
Department of Oncology, Mayo Clinic, Rochester, MN.
出版信息
J Clin Oncol. 2024 Feb 1;42(4):373-377. doi: 10.1200/JCO.23.01982. Epub 2023 Nov 14.
Abstract
摘要
相似文献
1
Neoadjuvant Immunotherapy in Gastroesophageal Cancer: A Promising Early Signal?
J Clin Oncol. 2024 Feb 1;42(4):373-377. doi: 10.1200/JCO.23.01982. Epub 2023 Nov 14.
2
ASO Author Reflections: Neoadjuvant Chemotherapy Combined with Immunotherapy is a Promising Strategy for Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma.
Ann Surg Oncol. 2024 Nov;31(12):8179-8180. doi: 10.1245/s10434-024-16152-5. Epub 2024 Aug 30.
3
The growing pains of neoadjuvant trials for gastroesophageal carcinoma.
Ann Surg Oncol. 2006 Mar;13(3):285-7. doi: 10.1245/ASO.2006.09.916. Epub 2006 Feb 1.
4
Chemotherapy and novel targeted therapies for operable esophageal and gastroesophageal junctional cancer.
Best Pract Res Clin Gastroenterol. 2018 Oct-Dec;36-37:45-52. doi: 10.1016/j.bpg.2018.11.005. Epub 2018 Nov 22.
5
Neoadjuvant and adjuvant approaches in gastroesophageal cancers.
Curr Opin Oncol. 2023 Jul 1;35(4):318-325. doi: 10.1097/CCO.0000000000000950. Epub 2023 May 3.
6
Neoadjuvant treatment of adenocarcinomas of the gastroesophageal junction and stomach - a feasibility trial combining cisplatin and docetaxel with either 5-fluorouracil or capecitabine.
Int J Clin Pharmacol Ther. 2010 Jul;48(7):451-2. doi: 10.5414/cpp48451.
7
Predictors of overall and recurrence-free survival after neoadjuvant chemotherapy for gastroesophageal adenocarcinoma: Pooled analysis of individual patient data (IPD) from randomized controlled trials (RCTs).
Eur J Surg Oncol. 2017 Aug;43(8):1550-1558. doi: 10.1016/j.ejso.2017.05.005. Epub 2017 May 18.
8
[Perioperative chemotherapy vs. surgery alone in resectable gastroesophageal carcinomas. Results of the MAGIC study].
Chirurg. 2006 Dec;77(12):1166-7. doi: 10.1007/s00104-006-1249-5.
9
Two-Year Outcomes and Biomarker Analysis of Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma After Neoadjuvant Chemotherapy and Immunotherapy from the Phase II WuhanUHGI001 Trial.
Ann Surg Oncol. 2024 Nov;31(12):8157-8169. doi: 10.1245/s10434-024-16041-x. Epub 2024 Aug 17.
10
Gastroesophageal cancer: Navigating the immune and genetic terrain to improve clinical outcomes.
Cancer Treat Rev. 2020 Mar;84:101950. doi: 10.1016/j.ctrv.2019.101950. Epub 2019 Dec 10.
引用本文的文献
1
Efficacy of perioperative and neoadjuvant therapies in gastric and gastroesophageal junction adenocarcinoma: a network meta-analysis.
Oncologist. 2025 Aug 4;30(8). doi: 10.1093/oncolo/oyaf157.
2
Neoadjuvant arterial infusion chemotherapy combined with immunotherapy in treating locally advanced lower esophageal and esophagogastric junction cancer.
J Thorac Dis. 2025 Apr 30;17(4):2273-2285. doi: 10.21037/jtd-24-1908. Epub 2025 Apr 23.
3
S2303: phase II/III trial of paclitaxel + ramucirumab ± nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE).
Future Oncol. 2025 May;21(11):1325-1331. doi: 10.1080/14796694.2025.2485020. Epub 2025 Mar 28.
4
Effects of chemoradiotherapy on surface PD-L1 expression in esophageal cancer and its implications for immunotherapy.
Front Immunol. 2024 Dec 23;15:1509051. doi: 10.3389/fimmu.2024.1509051. eCollection 2024.
本文引用的文献
1
Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial.
J Clin Oncol. 2024 Feb 1;42(4):410-420. doi: 10.1200/JCO.23.00975. Epub 2023 Nov 14.
2
Programmed death-ligand 1 (PD-L1) expression in primary gastric adenocarcinoma and matched metastases.
J Cancer Res Clin Oncol. 2023 Nov;149(14):13345-13352. doi: 10.1007/s00432-023-05142-x. Epub 2023 Jul 25.
3
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.
N Engl J Med. 2023 Aug 10;389(6):491-503. doi: 10.1056/NEJMoa2302983. Epub 2023 Jun 3.
4
High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma.
Mod Pathol. 2023 May;36(5):100154. doi: 10.1016/j.modpat.2023.100154. Epub 2023 Mar 15.
5
Multi-Institutional Study of Pathologist Reading of the Programmed Cell Death Ligand-1 Combined Positive Score Immunohistochemistry Assay for Gastric or Gastroesophageal Junction Cancer.
Mod Pathol. 2023 May;36(5):100128. doi: 10.1016/j.modpat.2023.100128. Epub 2023 Feb 13.
6
Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM.
Int J Cancer. 2023 Jul 1;153(1):153-163. doi: 10.1002/ijc.34495. Epub 2023 Mar 23.
7
Deletion of PD-1 destabilizes the lineage identity and metabolic fitness of tumor-infiltrating regulatory T cells.
Nat Immunol. 2023 Jan;24(1):148-161. doi: 10.1038/s41590-022-01373-1. Epub 2022 Dec 28.
8
The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction.
Nat Commun. 2022 Nov 10;13(1):6807. doi: 10.1038/s41467-022-34403-5.
9
Indirect Clinical Validation of a Programmed Death-Ligand 1 Laboratory-Developed Test for Gastric/Gastroesophageal Junction Adenocarcinoma with 22C3 Antibody Concentrate.
Mol Diagn Ther. 2022 Nov;26(6):679-688. doi: 10.1007/s40291-022-00605-2. Epub 2022 Sep 20.
10
Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials.
JAMA Oncol. 2022 Oct 1;8(10):1456-1465. doi: 10.1001/jamaoncol.2022.3707.
Zotero 插件